Cellect Biotechnology Ltd. was founded in 2011 by Dr. Shai Yarkoni and Kasbian Nuriel Chirich, with a vision of enabling regenerative medicine to become reality.
Realizing that stem cells are one of the pillars of the 21st century medicine, first development was around enabling the mass enrichment of stem cells as a raw material for any and all regenerative treatments. Without such technologies, stem cells based treatments will remain within the confines of laboratories and clinical trials.
For regenerative medicine to become publicly available for all people, quality stem cells need to become a commodity, easily available in mass for all medicinal purposes.
Cellect was driven by its wish to become the main provider of technologies for pharma companies and medical centers that will make the production of stem cells based products a trivial, safe and inexpensive process.
Based on 15 years of in depth research, Cellect's ApoGraft is the long sought-after methodology that achieves that dream. Backed by 7 families of patents, Cellects’ ApoGraft is aimed at becoming the industry-wide standard for enabling the use of stem cells in a myriad of regenerative medicine treatments.